SCTX Stock Forecast: Scribe Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile.
SCTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Scribe Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (60): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Scribe Therapeutics, Inc. — and when they’d sell — is the membership.
SCTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SCTX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SCTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Scribe Therapeutics, Inc. (SCTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 9.3×
- Price / book
- —
- EV / EBITDA
- −5.5×
Cheaper than 15% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- −87.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −556.5%
- Net margin
- −98.5%
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 6% of US stocks
- Return on equity
- 15.2%
- Return on assets
- −27.9%
- Dividend yield
- —
Higher than 75% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SCTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCTX appears on the weeks it earns a place.
Frequently asked questions about SCTX stock
How does Ticker Nerd's model rank SCTX?
As at 1 Aug 2026, Scribe Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (60 of 100).
What is the SCTX stock forecast for 2030?
No analyst covering Scribe Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCTX are extrapolating price history, which says nothing about the business.
What does Scribe Therapeutics, Inc. do?
Scribe Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of in vivo CRISPR-based genetic medicines for highly prevalent cardiometabolic diseases.
About Scribe Therapeutics, Inc.
Scribe Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of in vivo CRISPR-based genetic medicines for highly prevalent cardiometabolic diseases. The company engineers purpose-built gene editing and epigenetic silencing therapies designed to modify disease-driving biology directly in the body, with an emphasis on durable intervention without permanent changes to DNA when possible. Its lead program, STX-1150, is a liver-targeted therapy that uses ELXR epigenetic silencing technology to repress the PCSK9 gene, aiming to durably lower LDL cholesterol by modulating a well-validated cardiovascular risk factor. Additional pipeline candidates, including programs targeting Lp(a) and triglycerides via the LPA and APOC3 genes, extend its focus across key drivers of atherosclerotic cardiovascular disease. Scribe Therapeutics applies its proprietary CRISPR by Design platform, incorporating advanced molecular engineering and validation methods to enhance specificity and therapeutic precision. Founded in 2017 and headquartered in Alameda, California, Scribe Therapeutics operates today at the intersection of gene editing and cardiometabolic medicine, serving the broader genetic medicine and healthcare sectors.
CEO Dr. Benjamin L. Oakes Ph.D. · 89 employees · United States · https://www.scribetx.com